Quaker BioVentures II LP 4
4 · TELA Bio, Inc. · Filed Nov 13, 2019
Insider Transaction Report
Form 4
TELA Bio, Inc.TELA
Quaker BioVentures II LP
10% Owner
Transactions
- Conversion
Series B Preferred Stock
2019-11-13−12,763,434→ 0 total→ Common Stock (516,947 underlying) - Conversion
Warrant (right to buy)
2019-11-13−446,813→ 0 totalExercise: $1.16From: 2017-01-18Exp: 2027-01-18→ Series B Preferred Stock (446,813 underlying) - Purchase
Common Stock
2019-11-08$13.00/sh+153,846$1,999,998→ 888,664 total - Conversion
Common Stock
2019-11-13+345,489→ 1,234,153 total - Conversion
Common Stock
2019-11-13+516,947→ 1,751,100 total - Conversion
Series A Preferred Stock
2019-11-13−8,530,145→ 0 total→ Common Stock (345,489 underlying) - Conversion
Warrant (right to buy)
2019-11-13−446,813→ 446,813 totalExercise: $28.65From: 2019-11-13Exp: 2027-01-18→ Common Stock (18,096 underlying)
Footnotes (5)
- [F1]Reflects 705,530 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
- [F2]Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F3]Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F4]Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
- [F5]Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.